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The c-MET receptor can be overexpressed, amplified, or mutated in solid tumours including small cell lung cancer (SCLC). In
c-MET-overexpressing SCLC cell line NCI-H69, hepatocyte growth factor (HGF) dramatically induced c-MET phosphorylation at
phosphoepitopes pY1230/1234/1235 (catalytic tyrosine kinase), pY1003 (juxtamembrane), and also of paxillin at pY31 (CRKL-
binding site). We utilised a global proteomics phosphoantibody array approach to identify further c-MET/HGF signal transduction
intermediates in SCLC. Strong HGF induction of specific phosphorylation sites in phosphoproteins involved in c-MET/HGF signal
transduction was detected, namely adducin-a [S724], adducin-g [S662], CREB [S133], ERK1 [T185/Y187], ERK1/2 [T202/Y204], ERK2
[T185/Y187], MAPKK (MEK) 1/2 [S221/S225], MAPKK (MEK) 3/6 [S189/S207], RB [S612], RB1 [S780], JNK [T183/Y185], STAT3
[S727], focal adhesion kinase (FAK) [Y576/S722/S910], p38a-MAPK [T180/Y182], and AKT1[S473] and [T308]. Conversely,
inhibition of phosphorylation by HGF in protein kinase C (PKC), protein kinase R (PKR), and also CDK1 was identified.
Phosphoantibody-based immunohistochemical analysis of SCLC tumour tissue and microarray established the role of c-MET in SCLC
biology. This supports a role of c-MET activation in tumour invasive front in the tumour progression and invasion involving FAK and
AKT downstream. The c-MET serves as an attractive therapeutic target in SCLC, as shown through small interfering RNA (siRNA)
and selective prototype c-MET inhibitor SU11274, inhibiting the phosphorylation of c-MET itself and its downstream molecules such
as AKT, S6 kinase, and ERK1/2. Investigation of mechanisms of invasion and, ultimately, metastasis in SCLC would be very useful with
these signal transduction molecules.
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The c-MET receptor tyrosine kinase (c-MET RTK) is the receptor
for hepatocyte growth factor/scatter factor (HGF/SF; Jeffers et al,
1996). The mature HGF protein binds to its high-affinity receptor
c-MET, leading to its activation and phosphorylation of multiple
serine and tyrosine residue sites. The extracellular Sema domain
of c-MET mediates binding to the ligand HGF, which, subse-
quently, leads to receptor dimerisation and activation of its
intrinsic tyrosine kinase (Kong-Beltran et al, 2004; Stamos et al,
2004). The c-MET/HGF pathway has gained considerable interest
through its apparent deregulation by overexpression or gain-of-
function mutations in c-MET in various cancers, including lung
cancer (Maulik et al, 2002c; Ma et al, 2003b; Christensen et al,
2005). We have shown that cell motility of small cell lung cancer
(SCLC) cells is increased after HGF stimulation (Maulik et al,
2002a). Through PI3K pathway, HGF also stimulates activation of
the cytoskeletal focal adhesion proteins paxillin, focal adhesion
kinase (FAK) and PYK2 in SCLC (Maulik et al, 2002a,b).
Small cell lung cancer is a very difficult disease with very poor
prognosis and distant metastasis is often present at diagnosis
(Murray et al, 2004). Small cell lung cancer comprises of about
15% of all lung cancers and is invariably associated with cigarette
smoking. Novel therapy for this aggressive disease is urgently
needed (Ma and Salgia, 2004; Sattler et al, 2004; Choong et al,
2005). The aggressiveness of the tumour is shown by its high
propensity of organ invasion and metastasis to the brain, lymph
nodes, liver, bone, leptomeninges, and also the bone marrow.
Deregulation of cell motility may be tightly linked to tumour
invasion, a process distinct from tumour progression. During
invasion, cells degrade or remodel the surrounding extracellular
matrix and migrate through the tissue boundary (Kermorgant
et al, 2001). We have previously shown that c-MET/HGF pathway
is functional and c-MET is often mutated in SCLC (Ma et al,
2003a). Our recent studies also show that c-MET is mutated
in non-SCLC (NSCLC; Ma et al, 2005) and mesothelioma
(Jagadeeswaran et al, 2006). Further studies of the role of
c-MET/HGF signalling in SCLC will help to improve the
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sunderstanding of the mechanism of invasion and metastasis in this
aggressive disease.
The molecular mechanisms behind HGF-dependent invasive
growth are not fully understood and have just begun to be
elucidated. It has been suggested that c-MET leads to the induction
of genes that are actively involved in invasion and metastasis.
In vivo, the invasive-growth programming from c-MET/HGF
signalling is thought to be an integrated function of a variety of
biological responses such as cell proliferation and survival, cell
dissociation/scattering, motility, induction of cell polarity, angio-
genesis, wound healing, tissue regeneration, invasion, and tumour
metastasis (Stella and Comoglio, 1999; Comoglio, 2001; Comoglio
and Trusolino, 2002; Maulik et al, 2002c; Ma et al, 2003b).
Here we utilised a phosphoantibody array-based approach to
study the phosphoproteome of SCLC c-MET/HGF signalling
pathway. We have identified induction and inhibition of
phosphorylation in numerous phosphoepitopes of phosphopro-
teins. These signalling pathway intermediates are found in diverse
cellular regulatory signalling axis, including cell proliferation,
survival, cell cycle, cytoskeletal functions, and transcription. With
tumour tissue microarray (TMA) and phosphoantibody immuno-
staining, we also gained further insight into the role of c-MET/
HGF signalling in SCLC biology and tumour invasion. Finally,
novel targeted therapeutics against c-MET in SCLC was validated
by small interfering RNA (siRNA) and the c-MET inhibitor
SU11274.
MATERIALS AND METHODS
Cell lines and cell culture
Small cell lung cancer cell line NCI-H69 was purchased from the
American Type Culture Collection (Rockville, MD, USA) and
maintained in RPMI-1640 (Cellgro, Herndon, VA, USA) supple-
mented with 10% (v/v) fetal calf serum (FCS), L-glutamate, sodium
pyruvate, and HEPES buffer as described previously (Ma et al,
2003a). Cells were deprived of growth factors by incubation in
starvation media RPMI-1640 containing 0.5% (w/v) BSA (Sigma, St
Louis, MO, USA) for 18h before stimulation experiment with HGF
(40ngml
 1 for 7.5min).
c-MET inhibitor
SU11274 was provided by Pfizer Inc. (R&D, La Jolla, CA, USA) and
was used as described previously (Ma et al, 2005). Small cell lung
cancer NCI-H69 cells were treated with and without SU11274 in the
presence of HGF (40ngml
 1, 7.5min) stimulation.
Phosphoantibody array (Kinetworkst)
Global proteomics phosphoantibody array-based approach to
analyse the signal transduction pathways of c-MET/HGF axis in
SCLC NCI-H69 cell line was performed utilising the Kinetworks
Phospho-Site Screen (KPSS)-1.3 and 2.0 (Kinexus, Vancouver,
British Columbia, Canada). A wide range of phosphorylation site-
specific antibodies were used in a qualitative and quantitative
fashion as a specific assay for regulation of diverse cell signal-
ling pathways (http://www.kinexus.ca/KPSS.htm). Kinetworks
Phospho-Site Screen 1.3 and KPSS-2.0 track 31 and 37 known
phosphorylation sites, respectively in phosphoproteins with
antibodies that recognise specific phosphorylated epitopes of the
target proteins (Supplementary Tables S1 and S2). A total of 350mg
of whole cell lysates from H69 cells with or without HGF
stimulation was used for each KPSS phosphoantibody array
screen, which is an antibody-based method (Kinetworks) that
relies on sodium dodecyl sulphate (SDS)-polyacrylamide minigel
electrophoresis and multilane immunoblotters to permit the
specific and quantitative detection of numerous protein kinases
(PK) or other signal transduction proteins simultaneously (Pelech
et al, 2003). Each blot was scanned densitometrically for
quantitation, with each blot having its own unique Kinexus
scan identification number. The trace quantity of a band was
measured by the area under its intensity profile curve
(units¼intensity mm). The trace quantity of a band is
represented as c.p.m. corrected to a scan time of 60s. The c.p.m.
was then normalised to correct for differences in protein amount.
Transfection and small interfering RNA
Small cell lung cancer cell line NCI-H69 was used in transfection
study with siRNA targeting against c-MET as described previously
(Ma et al, 2005), according to the manufacturer’s instructions
(Dharmacon Inc., Layayette, CO, USA).
Immunoblotting, tumour tissue microarray and
immunohistochemistry
Cellular proteins were extracted from whole cells using lysis buffer
as described previously (Ma et al, 2005). Immunoblotting was
performed using the following antibodies: anti-total c-MET (C-12;
Santo Cruz Biotechnology, Santa Cruz, CA, USA), p-MET [Y1230/
1234/1235] (BioSource, Camarillo, CA, USA), p-AKT [S473]
(Abcam, Cambridge, MA, USA), p-ERK1/2 [T202/Y204] (Bio-
Source), p-S6 kinase [T389] (Cell Signaling, Beverly, MA, USA),
and b-actin (Santa Cruz) as loading control. Lung tumour tissue
samples were collected with informed consent and in accordance
with Institutional Review Board (IRB) approval protocols at the
University of Chicago. Tumour tissue microarray was built using
the ATA-27 Arrayer (1-mm punch size) from Beecher Instruments
Inc. (Sun Prairie, WI, USA). The tumour microarray consists of
nine SCLC tumour samples, and, as controls, two lung adnocarci-
noma specimens. Corresponding normal lung or adjacent normal
tissues were included in the microarray as negative controls as
well. Each specimen was included in duplicates in the array.
Tumour tissue immunohistochemistry (IHC) staining was per-
formed using standard techniques as described previously (Ma
et al, 2005) with antibodies against the following proteins: HGF
(Zymed-Invitrogen, Carlsbad, CA, USA), c-MET (3D4 monoclonal;
Zymed-Invitrogen), p-MET [Y1003] or [Y1230/1234/1235], p-FAK
[Y861] (polyclonal; BioSource), FAK (Santa Cruz), p-AKT [S473]
(Abcam), phosphotyrosine (p-Tyr; 4G10; Upstate, Lake Placid, NY,
USA), and Ki-67 (mouse monoclonal: clone Ki-S5, DAKO,
Carpinteria, CA, USA). In addition, similar IHC was performed
on an archival paraffin-embedded SCLC tumour sections for
topographic analysis of the c-MET/HGF signalling pathway.
RESULTS
c-MET/HGF signalling in small cell lung cancer identified
via phosphoantibody array-based phosphoproteomics
approach
We have previously demonstrated that c-MET/HGF signalling
pathway is functional in SCLC NCI-H69 cell line (Maulik et al,
2002a,b). The c-MET receptor tyrosine kinase is overexpressed in
H69 cells and is inducible by exogenous HGF, resulting in
induction of tyrosine phosphorylation at the major autophos-
phorylation sites pY1230/1234/1235 in the catalytic kinase
domain, and also the pY1003 site in the juxtamembrane domain
of c-MET (Figure 1). In addition, HGF induction of the c-MET
receptor causes stimulation of cell motility and cell–cell aggrega-
tion of NCI-H69 cells in culture, correlating with induction of
tyrosine phosphorylation of a number of focal adhesion proteins
such as paxillin, FAK, and PYK2 (Maulik et al, 2002a). In our
study, strong HGF induction of phosphorylation was readily
detectable in a number of specific phosphorylation sites in
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sphosphoproteins, downstream of c-MET itself, that are involved in
c-MET/HGF signal transduction in SCLC NCI-H69 cells (Figures
2A and B).
A diverse set of phosphoproteins pivotal in a wide range of
cellular regulation, consistent with the known pleiotropic effects of
c-MET/HGF signalling, were identified. These include phospho-
proteins that regulate transcriptional control: STAT3 [S727] and
CREB [S133]; cell cycle G1/S checkpoint: RB [S612], RB1 [S780];
cell survival and apoptosis: AKT1 [S473] and [T308], JNK [T183/
Y185]; cell proliferation and differentiation: MAPKK (MEK) 1/2
[S221/S225], ERK1 [T185/Y187], ERK2 [T185/Y187], ERK1/2
[T202/Y204]; stress and inflammatory response to cytokines and
growth factors: MAPKK (MEK) 3/6 [S189/S207], p38a-MAPK
[T180/Y182]; and also JNK [T183/Y185]; cytoskeletal functions:
FAK [Y576/S722/S910], adducin-a [S724], and adducin-g [S662].
Increased adducin expression has also been implicated in cell
proliferation (Bowen et al, 2003).
Conversely, we also identified modest inhibition of phosphory-
lation by HGF in the following phosphoproteins (Figures 2A and
B): PKCa [S657], PKCa/b [T368/641], and PKCd [T505]. Moreover,
HGF also inhibited phosphorylation of PKR [T451], which is
known to have antiproliferative and pro-apoptotic functions.
Lastly, HGF also reduced the threonine and tyrosine phosphoryla-
tion of the cell cycle checkpoint regulator CDK1 [T14/Y15].
Downstream cellular signal transduction pathways
induced by HGF
Compared with the untreated control of the SCLC NCI-H69 cells,
HGF stimulation at 40ngml
 1 for 7.5min caused an induction of
phosphorylation of the following phosphoprotein phosphosites
(Figure 2C): adducin-a [S724] (146%), adducin-g [S662] (125%),
CREB [S133] (143%), ERK1 [T185/Y187] (449%), ERK1/2 [T202/
Y204] (558%), ERK2 [T185/Y187] (289%), MAPKK (MEK) 1/2
[S221/S225] (183%), MAPKK (MEK) 3/6 [S189/S207] (118%), RB
[S612] (146%), RB1 [S780] (197%), JNK [T183/Y185] (163%),
STAT3 [S727] 139%), FAK [Y576] (132%), FAK [S722] (123%),
FAK [S910] (165%), p38a-MAPK [T180/Y182] (136%), and AKT1
[S473] (166%) and [T308] (207%).
Downstream cellular signal transduction pathways
inhibited by HGF
Treatment of the H69 cells by HGF (40ngml
 1; 7.5min) caused a
reduction of phosphorylation in the following phosphoproteins at
the specified phosphosites (Figure 2D): PKCa [S657] (39%
reduction), PKCa/b [T368/641] (36% reduction), PKCd [T505]
(30% reduction), PKR [T451] (46% reduction), and also CDK1
[T14/Y15] (38% reduction).
c-MET/HGF signalling pathways in SCLC cytoskeletal
functions
Substantial evidence has been culminated to support the key role
of c-MET/HGF signalling in mediating cell motility and cytoske-
letal functions in SCLC (Maulik et al, 2002a,b; Ma et al, 2003a).
Phosphorylation of the focal adhesion proteins paxillin, FAK, and
PYK2 are all inducible in response to HGF stimulation (Maulik
et al, 2002a). Here, we also showed that HGF induced other
phosphorylation sites on FAK, namely [Y576] (132%), [S722]
(123%), and [S910] (165%; Figure 3). There have been reports on
the role of PKC in focal adhesions and cell motility (Anilkumar
et al, 2003). There are a number of phosphorylation sites on
various PKC isoforms that can be inhibited by HGF, particularly
PKCa [S657] (39% reduction), PKCa/b [T368/641] (36% reduc-
tion), and PKCd [T505] (30% reduction). In SCLC NCI-H69 cells,
HGF also induced phosphorylation on adducin-a [S724] (146%),
and adducin-g [S662] (125%), which have not been reported
earlier.
SCLC invasion as related to c-MET/HGF axis
To understand better the role of the in vivo c-MET/HGF signalling
in SCLC tumour tissues, we performed IHC analysis in SCLC
tumours, as established on a tissue microarray. Various phos-
phospecific antibodies were used in the IHC analysis to provide
both qualitative and quantitative information of the signalling
pathways in the tumours (Figure 4). We found that there was 100%
positive (moderate, 78% (7/9); strong, 22% (2/9)) expression of
HGF in SCLC, with predominantly intratumoural cytoplasmic
staining pattern. This finding supports the notion of an autocrine
c-MET/HGF signalling in SCLC. There was 78% (7/9) of SCLC
expressing c-MET positively, in which 42% (3/7) had weak, 29%
(2/7) had moderate, and 29% (2/7) had strong expression.
Furthermore, we identified 56% (5/9) pY1003-MET and 33% (3/9)
pY1230/1234/1235-MET-positive expression in the SCLC TMA.
There were 56% (5/9) SCLC samples that had p-Tyr expression,
all with strong (3þ) IHC staining. It is interesting to note that
p-ERK1/2 staining was uniformly strong (3þ) in its staining
pattern in 89% (8/9) positive samples. The Ki-67 staining was
positive in 89% (8/9) SCLC samples. Positive staining in p-FAK
[pY861] and p-AKT [pS473] were seen in 67 and 56% of samples,
respectively (Figure 5).
Tumour tissue microarray analysis allows simultaneous analysis
of a number of different phosphoproteins both within the same
tumour tissue core and also among different tumour tissues.
Analysis of both the IHC staining patterns of p-MET and Ki-67
indicates that the strong staining intensities do not coincide within
the same tumours, suggesting that activated p-MET does not
necessarily activate the cell proliferation pathway. On the other
hand, p-MET (especially pY1003) staining coincided with p-FAK
and p-AKT expression, suggesting the role of c-MET activation in
cell migration, invasion, and survival. None of the three normal
lung or paired normal tissues in the TMA showed any expression
of either c-MET or p-MET.
Analysis of c-MET/HGF signalling activation in SCLC
tumour tissues
We also studied the role of c-MET/HGF signalling pathway in
SCLC tumour tissues using phosphospecific antibodies IHC
analysis with focus on its topographic pattern of expression. The
downstream signalling molecules p-AKT [S473] and p-FAK [Y861]
were studied in addition to HGF, c-MET, p-MET (both Y1003 and
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Figure 1 Induction of c-MET phosphorylation by HGF. HGF induction of
tyrosine phosphorylation of c-MET at the phosphoepitopes p-MET
[pY1003], the juxtamembrane c-CBL-binding site, and p-MET [pY1230/
1234/1235], the cytoplasmic catalytic kinase domain autophosphorylation
site as confirmed by immunoblotting is shown quantitatively here.
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Figure 2 (A) KPSS-1.3 phosphoantibody multi-immunoblot array. SCLC NCI-H69 cells were treated with or without HGF (40ngml
 1, 7.5min). The
WCLs were analysed using the KPSS-1.3 phosphoantibody multi-immunoblot array. The identities of phosphoprotein targets of interests are indicatedb y
arrows and abbreviations. (B) KPSS-2.0 phosphoantibody immunoblot array. SCLC NCI-H69 cells were treated with or without HGF (40ngml
 1, 7.5min).
The WCLs were analysed using the KPSS-2.0 phosphoantibody multi-immunoblot array The identities of phosphoprotein targets of interests are indicated
by arrows and abbreviations. (C) c-MET/HGF signalling transduction in SCLC: phosphoproteins induced by HGF. The phosphoproteins downstream of
c-MET found to be induced by HGF in SCLC in Kinetworks KPSS-1.3 and KPSS-2.0 are shown here. The specific phosphoepitopes induced are indicated. (D)
c-MET/HGF signalling transduction in SCLC: phosphoproteins inhibited by HGF. The phosphoproteins downstream of c-MET found to be inhibited by HGF
in SCLC in Kinetworks KPSS-1.3 and KPSS-2.0 are shown here. The specific phosphoepitopes inhibited are indicated.
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sY1230/1234/1235), and p-Tyr. In one of the four SCLC tumour
tissues (25%) screened, preferential c-MET overexpression and
activation of p-MET (both the phosphoepitopes pY1003 and
pY1230/1234/1235) along the tumour expanding invasive front
were identified (Figures 5A and B). Similar observation was also
made in NSCLC tumour specimens (Figure 5F; Ma et al, 2005).
Hepatocyte growth factor staining was more uniform within the
SCLC tumour, with only slightly stronger staining along the
invasive edge (Figure 5C). Moreover, preferential staining with
p-FAK [Y861], p-AKT [S473], and also p-Tyr antibody (similar to
that of c-MET and p-MET) was seen along the invasive front in
SCLC (Figures 5D and E). Particularly evident in the case of anti-
p-Tyr immunostaining, there was an outwardly increasing gradient
of IHC staining intensity along the axis from the core towards the
peripheral invasive front (Figure 5A). The other three SCLC
tumour tissues screened were immunostained negative for both of
the p-MET antibodies.
Activated p-MET as a potential target for therapeutic
inhibition
Validation by siRNA against c-MET Next, we investigated the
potential role of targeting c-MET to inhibit SCLC. We utilised
c-MET-specific siRNA to knock down the c-MET signalling in the
SCLC NCI-H69 cells using standardised techniques as described
in the Materials and methods (Ma et al, 2005; Figure 6A). c-MET
receptor was substantially downregulated by siRNA-MET which
also correlated with a concomitant inhibition of p-MET as well as
its downstream signalling molecules p-AKT, p-ERK1/2, and p-S6
kinase (Figure 6A).
SU11274 inhibition of c-MET/HGF signalling We have previously
characterised and described the efficacy of the specific small
molecule inhibitor of c-MET (Sattler et al, 2003; Ma et al, 2005).
Here, we tested the inhibitor against the SCLC NCI-H69 cells in the
phosphokinase screen to study its effect on c-MET/HGF signalling
pathway components (Figure 6B). The HGF-stimulated phosphory-
lation of the following downstream phosphokinases was inhibited
by SU11274: p-ERK1 [T202/Y204], p-ERK1/2 [T185/Y187],
p-MEK1/2 [S221/S225], p38a p-MAP kinase [T180/Y182], p-AKT1
[S473], p-RB [S672], p-adducin-g [S662], and p-CREB [S133]).
SU11274 was also effective in abrogating the inhibitory effect of
HGF on the specific phosphorylation of p-PKCa [S657], p-PKCa/b
[T368], and p-CDK1 [T14/Y15] (Figure 6B).
DISCUSSION
The c-MET is a key receptor tyrosine kinase expressed predomi-
nantly in epithelial cells. The c-MET has been identified as an
oncogene with convincing evidence, demonstrating the direct key
roles of activating c-MET mutations and met amplification in
promoting tumorigenesis in vivo (Graveel et al, 2004, 2005). We
have previously demonstrated that c-MET/HGF pathway not only
is functional in SCLC, it also harbours novel mutations of c-MET
in the semaphorin and juxtamembrane domains (Maulik et al,
2002a; Kijima et al, 2003; Ma et al, 2003a). Here, we further
investigated the c-MET/HGF signalling pathway in SCLC with
focus on the phosphoproteome.
Hepatocyte growth factor dramatically induced phosphorylation
of c-MET at its various serine threonine tyrosine epitopes,
including the major autophosphorylation sites pY1230/1234/1235
within the catalytic tyrosine kinase domain, and the regulatory
juxtamembrane c-CBL-binding site pY1003. Hepatocyte growth
factor also dramatically enhanced SCLC cell motility with
concomitant induction of tyrosine phosphorylation of a number
of cellular proteins such as the focal adhesion proteins paxillin,
focal adhesion kinase (FAK), and PYK2. Here, we adopted a global
phosphoantibody array-based approach to delineate further the
c-MET/HGF signal transduction pathway and its downstream
signalling intermediates in the SCLC phosphoproteome. Using
SCLC NCI-H69 cells with and without HGF stimulation as the
model, the screening arrays KPSS-1.3 and KPSS-2.0 together
allowed detection of strong HGF-induction of specific phosphory-
lation sites in phosphoproteins downstream of c-MET itself, that
are involved in diverse cellular regulation, including transcrip-
tional control, cell cycle G1/S checkpoint, cell survival and
apoptosis, cell proliferation and differentiation, stress and
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Figure 3 c-MET/HGF signal transduction pathways in SCLC. A schematic diagram to illustrate the versatile signalling functions of c-MET/HGF pathway in
SCLC regulating various biological functions of the cells, including cytoskeletal functions, cell proliferation and differentiation, survival, and apoptosis is shown.
Various potential serine, threonine and tyrosine phosphorylation sites on the signalling phosphoprotein intermediates are included. "¼stimulatory;
~¼inhibitory.
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Figure 4 Tumour tissue microarray analysis of c-MET/HGF signalling. (A) Examples of the SCLC TMA tissues immunostained with HGF and c-MET
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sinflammatory response to cytokines and growth factors, as well as
cytoskeletal functions. Phosphoprotein epitopes that are inhibited
by HGF in their phosphorylation were also identified.
We have previously shown that cell motility of SCLC is
enhanced by ligand stimulation with HGF via c-MET RTK
(Weisberg et al, 1997; Maulik et al, 2002a). The serum level of
HGF is significantly higher in SCLC patients than that in normals.
Moreover, serum HGF level higher than 500pgml
 1 is associated
with a trend towards worse survival (Bharti et al, 2004). The
mechanism whereby HGF activation of c-MET leads to increased
motility, migration, and invasion in cancer cells has not been well-
defined. Hepatocyte growth factor-induced c-MET activation leads
to increased membrane ruffling, filopodia formation, and also
motility/migration in SCLC (Maulik et al, 2002a). Cell motility is
also regulated by the focal adhesions. c-MET/HGF signalling
has been shown to induce the formation of focal adhesions
(Matsumoto et al, 1995). The focal adhesion is comprised of multiple
nonenzymatic proteins including vinculin, a-actinin, paxillin, and
kinases such as FAK and PYK2. Focal adhesion kinase is a 125kDa
protein, consisting of an N-terminal integrin-binding site, a central
kinase domain, and a C-terminal focal adhesion-targeting and
paxillin-binding domains (Schaller and Sasaki, 1997; Mitra et al,
2005). Focal adhesion kinase family members include proteins
such as PYK2 and FAK-B. Focal adhesion kinase is important
receptor-proximal regulator of cell shape, adhesion, and cell
motility. Focal adhesion kinase was discovered as a substrate of
SRC and is key to integrin signalling. It interacts with integrins and
other focal adhesion proteins such as paxillin, regulatory enzy-
matic signalling molecules such as PI3K, SH3 domain-containing
adapter proteins, and other tyrosine kinases via an autophos-
phorylation site at tyrosine residue 397 (pY397). Activation of the
pY397 autophosphorylation site of FAK promotes SRC binding,
leading to the conformational activation of SRC, and, subse-
quently, a dual activated FAK–SRC signalling complex (Mitra
et al, 2005). Within this FAK–SRC complex, SRC phosphorylates
FAK at pY861, associating with an increase in SH3-domain-
mediated binding of p130Cas to the FAK C-terminal proline-rich
regions, which, in turn, promotes cell motility and invasion (Lim
et al, 2004). Focal adhesion kinase [pY861] is also crucial for RAS-
mediated transformation of fibroblast (Lim et al, 2004). We have
recently shown that FAK was phosphorylated on pY397 (autophos-
phorylation site) and pY861 (the major SRC phosphorylation site)
in response to HGF in SCLC (Maulik et al, 2002a). With regard to
cell motility and migration, overexpression of FAK in MDCK cells
apparently enhances the cell migration component of the HGF-
induced cell scattering. Here, we also identified p-FAK [Y576],
[S722], and also [S910] to be induced by c-MET/HGF in H69 cells.
Focal adhesion kinase plays a central role in cell spreading,
differentiation, migration, cell death, and acceleration of the G1 to
S phase transition of the cell cycle. Tyr576 and Tyr577 are located
in the kinase activation loop of FAK and, when phosphorylated by
SRC, results in maximal activity. The role of phosphorylation at
Ser722 and Ser910 is currently being actively investigated. While
SRC is a known intermediate in c-MET/HGF signalling, we did not
observe induction of p-SRC [Y418] or [Y529] as included in the
KPSS screens. These specific phosphoepitope sites might not be
involved in the SRC activation by HGF-stimulated c-MET
signalling. Further work to catalogue various specific phospho-
epitope induction in the downstream signalling intermediates of
c-MET/HGF pathway through global phosphoproteomics analysis
would be very useful.
Cellular molecules regulating tumour cell motility and migration
are believed to be key element in promoting tumour invasion.
Evidence of signalling pathways regulating tumour cell invasion
may be found within the tumour itself through detailed IHC
analysis. The use of TMA can provide a platform to study a
number of different signalling molecules simultaneously on the
multiple tumour specimens, allowing both quantitative and
A
BC
D E
F
Normal lung
SCLC tumour tissue immunostain at the invasive front
SCLC: phosphotyrosine (p-Tyr)
c-MET HGF
p-AKT p-FAK
[pY1003]
[pYpYpY1230/1234/1235]
SCLC: pY1003-MET SCLC: pY1230/1234/1235-MET
Figure 5 Topographic analysis of the invasive front of SCLC using
phosphoantibody IHC. (A) Topographic role of p-MET and phospho-
proteins with pTyr activation. (B) Overexpression of c-MET along the
SCLC invasive tumour front,  10. Inset:  4. (C) Overexpression of
HGF in SCLC tumour tissue,  10. Inset:  4. (D) Topographic role of
activated cytoskeletal focal adhesion protein p-FAK,  10. Inset:  4. (E)
Topographic role of activated survival signalling molecule p-AKT,  10.
Inset:  4. (F) Preferential expression of activated p-MET along the tumour
invasive front in lung adenocarcinoma. Upper panel, p-MET [Y1003]. Lower
panel, p-MET [pY1230/1234/1235]. Magnification: left,  1; right,  4.
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squalitative analyses. Evidence to support the autocrine and
paracrine regulation of c-MET pathway was provided in the
TMA analysis in this study. Hepatocyte growth factor was
immunostained extensively in 100% of all the tumour tissues
examined, and there was intratumoural staining as well. Further-
more, its staining is more uniform across the tumour tissue itself
without preferential overexpression topographically. Interestingly,
there is a discordant staining pattern between p-MET and Ki-67 in
the TMA, suggesting that activation of p-MET might not always be
responsible for the SCLC cell proliferation and other regulatory
pathways might be at play. On the other hand, the immunostaining
of p-FAK [Y861] and p-AKT [S473] correlated well with that of the
p-MET, suggesting that c-MET is upstream of the two signalling
molecules FAK and AKT.
We have also examined in details the topographic distribution of
the various phosphoproteins in the c-MET/HGF pathway in SCLC
tumour tissue. Preferential staining of p-MET along the expanding
invasive front of the SCLC and adenocarcinoma tumour (Figure 5;
Ma et al, 2005) was evident. It suggests that there is preferential
activation of the c-MET receptors along the tumour invasive front
compared with the tumour core. Our findings here differ from the
recent report of the induction of c-MET overexpression by hypoxia
(Pennacchietti et al, 2003), a cellular state that is conceivably more
prominent within the tumour core than along the peripheral
expanding tumour front juxtaposing the adjacent lung alveoli.
Here, c-MET is found to be preferentially overexpressed and
activated along the peripheral tumour invasive front. Similarly, it
is also true for p-MET, as well as p-FAK and p-AKT, again
supporting the role of c-MET activation in cell survival, motility,
invasion, and metastasis in SCLC. Moreover, there was a gradient
of phosphotyrosine (p-Tyr) staining in the tumour tissue
examined (increasing gradient outward to tumour periphery).
This finding suggests that there are molecules in the tyrosine
phosphoproteome, some of which are likely to be downstream of
c-MET under its regulation, preferentially involved in the
regulation of SCLC tumour invasion and metastasis along the
invasive tumour front. In particular, FAK is an important tyrosine
kinase in the control of cytoskeletal function and cell motility. FAK
overexpression has also been shown to have synergistic effect with
HGF on cell transformation (Chan et al, 2002). Focal adhesion
kinase activation can also promote aggressive uveal and cutaneous
melanoma phenotype (Hess et al, 2005).
Recent molecular targeting in SCLC using c-KIT inhibitor
(Gleevec) and antisense BCL-2 (Oblisense) has been far from
successful (Johnson et al, 2003; Rudin et al, 2004). While SCLC is
mostly chemosensitive in frontline therapy, the inevitable disease
relapse in most patients and the subsequent chemoresistance
remain formidable problems leading to very poor overall outcome
(Ma and Salgia, 2004). The c-MET would be an attractive
therapeutic target to be inhibited in SCLC to expand the
therapeutic armamentarium. We show here that siRNA inhibition
of c-MET in SCLC significantly downregulates the activation of
p-AKT and p-S6 kinase in the cell survival pathway, and p-ERK1/2
in the proliferation pathway. Furthermore, the c-MET inhibitor
SU11274 can inhibit the activation of c-MET/HGF and its
downstream signal transducers. These data support further studies
and clinical development of inhibitors targeting c-MET in SCLC
(Ma et al, 2003b, 2005; Sattler et al, 2003, 2004; Christensen et al,
2005). c-MET/HGF-targeted therapy such as the specific inhibitor
SU11274 would be promising in at least a subset of SCLC patients
with deregulated c-MET signalling through its overexpression or
activating mutations. Multi-targeted kinase inhibitors to target
c-MET together with VEGFR2 (XL880; Exelixis Inc., San
Francisco, CA, USA) is also currently under development.
Moreover, antibody approach to inhibit the c-MET/HGF pathway
is also under investigation, both using antibodies against the
ligand (Burgess et al, 2006) as well as the receptor (Nguyen et al,
2003). Development of techniques of tumour tissue IHC with
phosphoantibodies of c-MET and its downstream signal trans-
ducers molecules would enable the validation of inhibitor efficacy
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Figure 6 c-MET as potential target for therapeutic inhibition – siRNA validation (A) and c-MET inhibitor SU11274 (B). (A) c-MET-specific siRNA (þ)
was used to downregulate c-MET expression in SCLC NCI-H69 cells in growth media containing 10% FCS as described previously (Ma et al, 2003a, 2005).
Cells treated with mock siRNA scramble sequence were included as negative control ( ). The WCLs were collected 72h after siRNA transfection and
analysed on 7.5% SDS–PAGE, and electrotransferred onto Immobilon-P membrane, and immunoblotted using the following antibodies: anti-total c-MET
(top panel), p-MET [pY1230/1234/1235] (second panel), p-AKT [S473] (third panel), p-ERK1/2 [T202/Y204] (fourth panel), p-S6 kinase [T389] (fifth panel),
and b-actin (bottom panel, loading control). (B) The WCLs of H69 cells treated with or without HGF and with or without SU11274 were collected and
analysed on the phosphoantibody-based multilane immunoblotting and quantitated as described in Materials and Methods. A number of phosphoproteins
were shown to be modulated by SU11274, both in the positive and negative fashion, in its inhibition against the c-MET/HGF signalling.
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inhibitors.
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